Market Overview

UPDATE: Citigroup Downgrades Edwards Lifesciences Corp. to Neutral, Lowers PT

Share:
Related EW
18 Biggest Mid-Day Gainers For Wednesday
Benzinga's Top Upgrades
Medtronic Misses High Expectations; St. Jude Dives On Hacking Claim (Investor's Business Daily)

In a report published Friday, Citigroup downgraded its rating on Edwards Lifesciences Corp. (NYSE: EW) from Buy to Neutral, and lowered its price target from $101.00 to $95.00.

Citigroup noted, “We rate Edwards Lifesciences (EW) Neutral. The near term ramp in US TAVI will likely take longer to materialize than originally expected despite recent approval of Cohort A, and combined with the macro issues in Europe that continue to add uncertainty to the global TAVI market, we believe visibility on the near-term market opportunity is limited despite believing that the longer-term opportunity remains intact.”

Edwards Lifesciences Corp. closed on Thursday at $86.14.

Latest Ratings for EW

DateFirmActionFromTo
Jul 2016JMP SecuritiesMaintainsMarket Outperform
Jul 2016UBSMaintainsBuy
Jul 2016CitigroupMaintainsSell

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Downgrades Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!